Industry News
Pharmaceutical Industry News
Focus on personalization,…
Focus on personalization, people-based data and patient context driving change
Wary European Drugmakers Think They Can Avoid Trump’s Latest Tariffs
European companies, a major source of U.S. medicines, are hopeful that their investments and trade deals with the U.S. will spare them from President Trump’s latest tariff barrage.
Spectrum Science’s Michelle…
Spectrum Science’s Michelle Gross on translating innovation into impact
In an expansion of its previous…
In an expansion of its previous moves to cut the price of insulin in the U.S., Sanofi now will cap the price for all of its insulin products at $35 per month regardless of a
AstraZeneca is the latest Big…
AstraZeneca is the latest Big Pharma to unveil a digital direct-to-consumer platform offering certain medicines at heavily reduced prices to cash-pay patients.
Amgen has spent the last three…
Amgen has spent the last three decades building out its presence in Puerto Rico. With a $650 million investment revealed Friday, the company's site in Juncos is set to grow again.
The 100% rate floated in Donald…
The 100% rate floated in Donald Trump’s new communique on pharmaceutical tariffs may appear steep, but the reality of the situation is likely less severe than it seems, multiple analysts wrote Friday following the president’s
Celltrion is buying an Eli Lilly…
Celltrion is buying an Eli Lilly plant in the U.S. for $330 million. The FDA has declined to approve Lundbeck and Otsuka's Rexulti in PTSD. Hengrui Pharma has out-licensed certain rights to its HER2 ADC
Serial entrepreneur Robert…
Serial entrepreneur Robert Wessman, who has had a golden touch creating, acquiring and spinning off companies that primarily sell generic drugs, has brought together two of his fastest-growing enterprises as Lotus Pharmaceuticals has acquired a 100%
Trump Will Slap Tariffs on Imported Drugs, Trucks and Household Furnishings
The president said his tariffs would range from 25 to 100 percent and go into effect next week.
Trump May Try to Force Drugmakers to Match European Prices
A federal website notice, deleted and then reposted by the administration, provides a hint that more aggressive pricing policies may be coming.
Eli Lilly has won the second FDA…
Eli Lilly has won the second FDA approval for an oral selective estrogen receptor degrader (SERD), albeit in a confined breast cancer indication like Menarini's drug before it.
At Fierce Pharma Week in…
At Fierce Pharma Week in Philadelphia, Veeva’s Anthony Billinger, Senior Director of Compass Strategy, emphasized the challenges drugmakers face in bringing new products to market, pointing to a persistent gap between forecasts and results. Studies
The FDA on Thursday signed off on…
The FDA on Thursday signed off on Crinetics’ paltusotine—now christened Palsonify—as a first-line treatment for certain adults with acromegaly. Unlike other somatostatin drugs that make up the bulk of current acromegaly care options, Palsonify is
Patients don’t just want to be…
Patients don’t just want to be reached. They want support that reduces barriers and makes progress easier. Here’s how pharma can deliver value that sustains engagement and adherence.
Hansa Biopharma has reported…
Hansa Biopharma has reported positive top-line results from a U.S. phase 3 trial of its antibody-cleaving enzyme imlifidase, which boasts conditional nods in the EU and several other countries to ease the kidney transplant process
Times Reporters Answer Your Vaccine Questions
We received hundreds of queries about efficacy, safety, cost and access.
On the heels of the launch of an…
On the heels of the launch of an online direct-to-patient program offering discounted Eliquis to certain U.S. patients, Bristol Myers Squibb is putting Sotyku at the center of its next DTP project.
With an appeal to the Supreme…
With an appeal to the Supreme Court, AstraZeneca is throwing one last Hail Mary following a string of Big Pharma defeats challenging the legality of the Inflation Reduction Act (IRA) Medicare price negotiation program.
Belén Garijo, who steered Merck…
Belén Garijo, who steered Merck KGaA through the COVID-19 pandemic, will step down as CEO of the German healthcare and electronics conglomerate.